JP2008508882A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508882A5
JP2008508882A5 JP2007524977A JP2007524977A JP2008508882A5 JP 2008508882 A5 JP2008508882 A5 JP 2008508882A5 JP 2007524977 A JP2007524977 A JP 2007524977A JP 2007524977 A JP2007524977 A JP 2007524977A JP 2008508882 A5 JP2008508882 A5 JP 2008508882A5
Authority
JP
Japan
Prior art keywords
rage
fusion protein
seq
fragment
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007524977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508882A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/027694 external-priority patent/WO2006017643A1/en
Publication of JP2008508882A publication Critical patent/JP2008508882A/ja
Publication of JP2008508882A5 publication Critical patent/JP2008508882A5/ja
Withdrawn legal-status Critical Current

Links

JP2007524977A 2004-08-03 2005-08-03 Ｒａｇｅ融合タンパク質及び使用方法 Withdrawn JP2008508882A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59836204P 2004-08-03 2004-08-03
PCT/US2005/027694 WO2006017643A1 (en) 2004-08-03 2005-08-03 Rage fusion proteins and methods of use

Publications (2)

Publication Number Publication Date
JP2008508882A JP2008508882A (ja) 2008-03-27
JP2008508882A5 true JP2008508882A5 (enExample) 2008-09-18

Family

ID=35427536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007524977A Withdrawn JP2008508882A (ja) 2004-08-03 2005-08-03 Ｒａｇｅ融合タンパク質及び使用方法

Country Status (23)

Country Link
US (2) US20060078562A1 (enExample)
EP (1) EP1776459A1 (enExample)
JP (1) JP2008508882A (enExample)
KR (1) KR20070057818A (enExample)
CN (1) CN101010430A (enExample)
AP (1) AP2007003893A0 (enExample)
AU (2) AU2005271449A1 (enExample)
BR (1) BRPI0514013A (enExample)
CA (1) CA2575830A1 (enExample)
CR (2) CR8897A (enExample)
EA (1) EA012586B1 (enExample)
EC (1) ECSP077297A (enExample)
GE (1) GEP20105111B (enExample)
IL (1) IL180555A0 (enExample)
MA (1) MA28781B1 (enExample)
MX (1) MX2007001556A (enExample)
NO (1) NO20070062L (enExample)
NZ (1) NZ552842A (enExample)
SG (1) SG161242A1 (enExample)
TN (1) TNSN07040A1 (enExample)
UA (1) UA92154C2 (enExample)
WO (1) WO2006017643A1 (enExample)
ZA (1) ZA200700641B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
WO2000020621A1 (en) * 1998-10-06 2000-04-13 The Trustees Of Columbia University In The City Of New York Extracellular novel rage binding protein (en-rage) and uses thereof
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
WO2002030889A2 (en) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
CN1774445A (zh) * 2002-08-16 2006-05-17 惠氏公司 用于治疗rage相关病症的组合物和方法
WO2004100890A2 (en) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Rage g82s-related methods and compositions for treating inflammatory disorders
US7470521B2 (en) * 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
MX2007001559A (es) * 2004-08-03 2007-04-10 Transtech Pharma Inc Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso.
CA2575830A1 (en) * 2004-08-03 2006-02-16 Transtech Pharma, Inc. Rage fusion proteins and methods of use
CA2581505A1 (en) * 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
BRPI0608401A2 (pt) * 2005-03-17 2010-11-16 Columbia Univ New York polipeptìdeo, composição farmacêutica, ácido nucleico, vetor de expressão, célula, métodos para inibir a ligação entre diáfano e o domìnio citoplasmático de rage, para identificar um agente que inibe a ligação entre o diáfano e o domìnio citoplasmático de rage, e, uso de um agente que inibe a ligação entre diáfano e o domìnio citoplasmático de rage
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
EP1963786B1 (en) * 2005-12-23 2013-07-24 GCoder Systems AB Positioning pattern
CN101410411A (zh) * 2006-02-09 2009-04-15 转化技术制药公司 Rage融合蛋白及使用方法
SG171670A1 (en) * 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
CA2915168C (en) 2007-01-30 2017-05-23 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
ES2564634T3 (es) * 2007-06-14 2016-03-28 Galactica Pharmaceuticals, Inc. Proteínas de fusión de RAGE
NL2001557C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001556C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001554C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001553C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001551C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001555C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001552C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001558C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2013103688A1 (en) * 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human soluble receptors for advanced glycation end products (srage), methods of preparing human srage, and treatment methods using srage
CN103376328A (zh) * 2013-07-18 2013-10-30 上海交通大学医学院附属瑞金医院 血清sRAGE水平的检测试剂在筛选改善胰岛素β细胞功能的糖尿病治疗药物中的应用
KR101645654B1 (ko) * 2014-05-02 2016-08-05 서울대학교산학협력단 Rage로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 뇌혈관질환의 예방 또는 치료용 약학적 조성물
EP3849578A4 (en) 2018-09-14 2022-06-22 Bioage Labs, Inc. Rage fusion proteins with improved stability and ligand binding affinity and uses thereof
JP7477141B2 (ja) * 2019-02-21 2024-05-01 国立研究開発法人農業・食品産業技術総合研究機構 肝疾患診断技術
JP7479039B2 (ja) * 2019-02-21 2024-05-08 国立研究開発法人農業・食品産業技術総合研究機構 糖尿病診断技術

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) * 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
FI119756B (fi) * 1995-01-18 2009-03-13 Alteon Inc Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa
CA2210684C (en) * 1995-01-18 2008-01-15 Alteon Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
AU5386996A (en) * 1995-04-05 1996-10-23 Picower Institute For Medical Research, The Agents for binding to advanced glycosylation endproducts, an d methods of their use
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
WO2000020621A1 (en) * 1998-10-06 2000-04-13 The Trustees Of Columbia University In The City Of New York Extracellular novel rage binding protein (en-rage) and uses thereof
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6380165B1 (en) * 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US20020102604A1 (en) * 1999-12-08 2002-08-01 Milne Edwards Jean-Baptiste Dumas Full-length human cDNAs encoding potentially secreted proteins
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
CA2382095A1 (en) * 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
PT1272843E (pt) * 2000-04-14 2007-10-01 Niadyne Corp Método para identificação de reguladores da formação de age de proteínas
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US7361678B2 (en) * 2002-03-05 2008-04-22 Transtech Pharma, Inc. Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
US6563015B1 (en) * 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
AU2001296959A1 (en) * 2000-10-02 2002-04-15 Reddy Us Therapeutics, Inc Methods and compositions for the treatment of inflammatory diseases
WO2002030889A2 (en) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US20050244849A1 (en) * 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
BR0116606A (pt) * 2000-12-29 2006-05-09 Reddy Us Therapeutics Inc métodos e composições para detecção de compostos que modulam as respostas inflamatórias
AU2002233340B2 (en) * 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
AU2002245590B2 (en) * 2001-03-05 2006-06-29 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
AU2002245591B2 (en) * 2001-03-05 2007-05-17 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
US6861888B2 (en) * 2002-01-16 2005-03-01 Agilent Technologies, Inc. High-sensitivity differential data latch system
CN1774445A (zh) * 2002-08-16 2006-05-17 惠氏公司 用于治疗rage相关病症的组合物和方法
WO2004100890A2 (en) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Rage g82s-related methods and compositions for treating inflammatory disorders
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
US6969545B2 (en) * 2003-07-28 2005-11-29 Deere & Company Hydrogen storage container
JP2007504247A (ja) * 2003-09-05 2007-03-01 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 糸球体損傷を治療するためのｒａｇｅに関連した方法および組成物
WO2005042782A1 (en) * 2003-10-31 2005-05-12 The Trustees Of Columbia University In The City Of New York Methods for reducing seizure-induced neuronal damage
US20070167360A1 (en) * 2003-10-31 2007-07-19 Yan Shi D Methods for treating multiple sclerosis
US7470521B2 (en) * 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
MX2007001559A (es) * 2004-08-03 2007-04-10 Transtech Pharma Inc Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso.
CA2575830A1 (en) * 2004-08-03 2006-02-16 Transtech Pharma, Inc. Rage fusion proteins and methods of use
CA2581505A1 (en) * 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
BRPI0608401A2 (pt) * 2005-03-17 2010-11-16 Columbia Univ New York polipeptìdeo, composição farmacêutica, ácido nucleico, vetor de expressão, célula, métodos para inibir a ligação entre diáfano e o domìnio citoplasmático de rage, para identificar um agente que inibe a ligação entre o diáfano e o domìnio citoplasmático de rage, e, uso de um agente que inibe a ligação entre diáfano e o domìnio citoplasmático de rage
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
CN101410411A (zh) * 2006-02-09 2009-04-15 转化技术制药公司 Rage融合蛋白及使用方法
SG171670A1 (en) * 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
US9491184B2 (en) * 2008-04-04 2016-11-08 Samsung Electronics Co., Ltd. Method and apparatus for managing tokens for digital rights management

Similar Documents

Publication Publication Date Title
JP2008508882A5 (enExample)
CN110144009B (zh) Cd47单域抗体及其用途
JP2008512988A5 (enExample)
CA2856141C (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
JP2022046510A (ja) 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン
PT1888641E (pt) Proteínas de ligação a albumina de soro
US20130129727A1 (en) Methods and systems for increasing protein stability
CN102686611A (zh) 与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法
PH12014501604B1 (en) Polypeptides binding to human complement c5
CN109796534B (zh) 抗il-17抗体/tnfr ecd融合蛋白及其用途
CN117304315B (zh) 抗il-6的纳米抗体及其在il-6相关疾病中的应用
JP2020535151A5 (enExample)
JP2008521426A5 (enExample)
CN116284374A (zh) 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
CN115109156A (zh) 一种靶向bcma的纳米抗体及其应用
CN109069591B (zh) 治疗和诊断纤维化或纤维化相关疾病的手段和方法
WO2021197359A1 (zh) 一种构建多特异性抗体的平台
CN116554317A (zh) Muc1结合分子及其应用
CN116199795B (zh) 融合蛋白及其用途
JP2019511457A5 (enExample)
CN116284405B (zh) 靶向cd150蛋白的纳米抗体及其应用
US20170114099A1 (en) New polypeptide
CN115873114A (zh) Ctla-4结合分子及其应用
RU2004114878A (ru) Агенты, увеличивающие аффинность
CN114685667A (zh) 间皮素结合分子及其应用